scholarly journals Clinical Drug-Drug Interaction Potential of BFE1224, Prodrug of Antifungal Ravuconazole, Using Two Types of Cocktails in Healthy Subjects

2018 ◽  
Vol 11 (5) ◽  
pp. 477-486 ◽  
Author(s):  
Yasuyuki Ishii ◽  
Yuko Ito ◽  
Shunji Matsuki ◽  
Kasumi Sanpei ◽  
Osamu Ogawa ◽  
...  
Keyword(s):  
Drug Interaction ◽  
Interaction Potential ◽  
Healthy Subjects ◽  
Drug Drug Interaction ◽  
Clinical Drug

scholarly journals No Effect of Digoxin on Rosuvastatin Pharmacokinetics in Healthy Subjects: Utility of Oita Combination for Clinical Drug–Drug Interaction Study

2019 ◽  
Vol 12 (5) ◽  
pp. 513-518 ◽  
Author(s):  
Naoyuki Otani ◽  
Hirokazu Wakuda ◽  
Hiromitsu Imai ◽  
Masae Kuranari ◽  
Yasuyuki Ishii ◽  
...  
Keyword(s):  
Drug Interaction ◽  
Healthy Subjects ◽  
Interaction Study ◽  
Drug Interaction Study ◽  
Drug Drug Interaction ◽  
Clinical Drug

scholarly journals Evaluation of Drug–Drug Interaction Potential between Baloxavir Marboxil and Oseltamivir in Healthy Subjects

2018 ◽  
Vol 38 (11) ◽  
pp. 1053-1060 ◽  
Author(s):  
Nao Kawaguchi ◽  
Hiroki Koshimichi ◽  
Toru Ishibashi ◽  
Toshihiro Wajima
Keyword(s):  
Drug Interaction ◽  
Interaction Potential ◽  
Healthy Subjects ◽  
Drug Drug Interaction

scholarly journals Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects

2020 ◽  
Vol 64 (7) ◽  
Author(s):  
Jason D. Lickliter ◽  
Kenneth Lawrence ◽  
John O’Donnell ◽  
Robin Isaacs
Keyword(s):  
Drug Interaction ◽  
Interaction Potential ◽  
Healthy Subjects ◽  
Controlled Study ◽  
Elderly Subjects ◽  
Content Type ◽  
Single And Multiple Doses ◽  
Multiple Doses ◽  
Drug Drug Interaction ◽  
Lactamase Inhibitor

ABSTRACT Durlobactam (DUR; also known as ETX2514) is a novel β-lactamase inhibitor with broad activity against Ambler class A, C, and D β-lactamases. Addition of DUR to sulbactam (SUL) in vitro restores SUL activity against clinical isolates of Acinetobacter baumannii. The safety and pharmacokinetics (PK) of DUR alone and with SUL and/or imipenem-cilastatin (IMI-CIL) were evaluated in healthy subjects. This was a randomized, placebo-controlled study. In part A, subjects, including a cohort of elderly subjects (which received DUR at 1 g), received single ascending doses of DUR ranging from 0.25 to 8 g. In part B, multiple ascending doses of DUR ranging from 0.25 to 2 g were administered every 6 h (q6h) for 29 doses. In parts C and D, the drug-drug interaction (DDI) potential, including the safety, of DUR (1 g) with SUL (1 g) and/or IMI-CIL (0.5/0.5 g) was investigated after single and multiple doses. Plasma and urine concentrations of DUR, SUL, and IMI-CIL were determined. Among 124 subjects, DUR was generally safe and well tolerated when it was administered either alone or in combination with SUL and/or IMI-CIL. After single and multiple doses, DUR demonstrated linear dose-proportional exposure across the studied dose ranges. Renal excretion was a predominant clearance mechanism. No drug-drug interaction potential between DUR and SUL and/or IMI-CIL was identified. SUL-DUR at 1 g (of each component) administered q6h with a 3-h intravenous (i.v.) infusion is under development for the treatment of serious infections due to A. baumannii. (This study has been registered at ClinicalTrials.gov under identifier NCT02971423.)

Pomalidomide: Evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects

2014 ◽  
Vol 55 (2) ◽  
pp. 168-178 ◽  
Author(s):  
Claudia Kasserra ◽  
Mahmoud Assaf ◽  
Matthew Hoffmann ◽  
Yan Li ◽  
Liangang Liu ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Drug Interaction ◽  
Interaction Potential ◽  
Healthy Subjects ◽  
Drug Drug Interaction
Sign in / Sign up

Export Citation Format

Share Document